Cell Administration Routes for Heart Failure: A Comparative Re-evaluation of the REGENERATE-DCM and REGENERATE-IHD Trials

References

• MacIntyreK , CapewellS , StewartSet al.Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation102(10), 1126–1131 (2000).
   PubMed Web of Science ®Google Scholar
• MosterdA , CostB , HoesAWet al.The prognosis of heart failure in the general population: the Rotterdam study. Eur. Heart J.22(15), 1318–1327 (2001).
   PubMed Web of Science ®Google Scholar
• WangY , XuF , MaJet al.Effect of stem cell transplantation on patients with ischemic heart failure: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res. Ther.10(1), 125 (2019).
   PubMed Web of Science ®Google Scholar
• JayarajJS , JanapalaRN , QaseemAet al.Efficacy and safety of stem cell therapy in advanced heart failure patients: a systematic review with a meta-analysis of recent trials between 2017 and 2019. Cureus11(9), e5585 (2019).
   PubMed Web of Science ®Google Scholar
• FisherSA , DoreeC , MathurAet al.Meta-analysis of cell therapy trials for patients with heart failure. Circ. Res.116(8), 1361–1377 (2015).
   PubMed Web of Science ®Google Scholar
• ReidA , MathurA. Cell-based regenerative therapy. In: The PCR-EAPCI Textbook.WijnsW, SerruysPW, VahanianA, EeckhoutE, DePalma R, van SambeekM ( Eds). Europa Digital and Publishing, Toulouse, France (2021).
   Google Scholar
• StrauerBE , SteinhoffG. 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice. J. Am. Coll. Cardiol.58(11), 1095–1104 (2011).
   PubMed Web of Science ®Google Scholar
• HamshereS , ArnousS , ChoudhuryTet al.Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: The REGENERATEDCM clinical trial. Eur. Heart J.36(44), 3061–3069 (2015).
   PubMed Web of Science ®Google Scholar
• ChoudhuryT , MozidA , HamshereSet al.An exploratory randomized control study of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with ischaemic cardiomyopathy: the REGENERATE-IHD clinical trial. Eur. J. Heart. Fail.19(1), 138–147 (2017).
   PubMed Web of Science ®Google Scholar
• HenryT , LosordoD , TraverseJet al.Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. Eur. Heart J.39(23), 2208–2216 (2018).
   PubMed Web of Science ®Google Scholar
• TripathiA , KhanMS , KhanARet al.Cell therapy for nonischemic dilated cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. Stem Cells Transl. Med.10(10), 1394–1405 (2021).
   PubMed Web of Science ®Google Scholar
• ZhaoXF , XuY , ZhuZYet al.Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure. Genet. Mol. Res.14(2), 3010–3017 (2015)
   PubMed Web of Science ®Google Scholar
• ArgüeroR , Careaga-ReynaG , Castaño-GuerraRet al.Cellular autotransplantation for ischemic and idiopathic dilated cardiomyopathy. preliminary report. Arch. Med. Res.37(8), 1010–1014 (2006).
   PubMed Web of Science ®Google Scholar
• HenryTD , TraverseJH , HammonBLet al.Safety and efficacy of ixmyelocel-T an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ. Res.115(8), 730–737 (2014).
   PubMed Web of Science ®Google Scholar
• BolliR , PerinEC , WillersonJTet al.Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: the CCTRN SENECA trial. JACC CardioOncology2(4), 581–595 (2020).
   PubMedGoogle Scholar
• ArnousS , MozidA , MathurA. The bone marrow derived adult stem cells for dilated cardiomyopathy (REGENERATE-DCM) trial: study design. Regen. Med.6(4), 525–533 (2011).
   PubMed Web of Science ®Google Scholar
• YeoC , MathurA. Autologous bone marrow-derived stem cells for ischemic heart failure: REGENERATE-IHD trial. Regen. Med.4(1), 119–127 (2009).
   PubMed Web of Science ®Google Scholar
• VrtovecB , PoglajenG , LezaicLet al.Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation128(Suppl. 11), S42–S49 (2013).
   PubMed Web of Science ®Google Scholar
• FisherSA , DoreeC , MathurAet al.Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst. Rev.12(12), CD007888 (2016).
   PubMedGoogle Scholar
• AttarA , BahmanzadeganJahromi F , KavousiSet al.Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials. Stem Cell Res. Ther.12(1), 600 (2021).
   PubMed Web of Science ®Google Scholar
• PackerM , KumbhaniDJ , BhattDL. Empagliflozin outcome trial in patients with chronic heart failure and a reduced ejection fraction – EMPEROR-Reduced. N. Engl. J. Med.383(15), 1413–1424 (2020).
   PubMed Web of Science ®Google Scholar
• VrtovecB , PoglajenG , LezaicLet al.Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ. Res.112(1), 165–173 (2013).
   PubMed Web of Science ®Google Scholar
• GuX , XieY , GuJet al.Repeated intracoronary infusion of peripheral blood stem cells with G-CSF in patients with refractory ischemic heart failure: a pilot study. Circ. J.75(4), 955–963 (2011).
   PubMed Web of Science ®Google Scholar
• PoglajenG , SeverM , CukjatiMet al.Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy. Circ. Cardiovasc. Interv.7(4), 552–559 (2014).
   PubMed Web of Science ®Google Scholar
• VrtovecB , PoglajenG , SeverMet al.Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. J. Card. Fail.17(4), 272–281 (2011).
   PubMed Web of Science ®Google Scholar
• LezaicL , SocanA , PoglajenGet al.Intracoronary transplantation of CD34+ cells is associated with improved myocardial perfusion in patients with nonischemic dilated cardiomyopathy. J. Card. Fail.21(2), 145–152 (2015).
   PubMed Web of Science ®Google Scholar
• VrtovecB , PoglajenG , SeverMet al.Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circ. Res.123(3), 389–396 (2018).
   PubMed Web of Science ®Google Scholar
• BocchiEA , BacalF , GuimarãesGet al.Granulocyte-colony stimulating factor or granulocyte-colony stimulating factor associated to stem cell intracoronary infusion effects in non ischemic refractory heart failure. Int. J. Cardiol.138(1), 94–97 (2010).
   PubMed Web of Science ®Google Scholar